Dyne Therapeutics
IPOA biotechnology company developing nucleic acid therapies for rare diseases.
Public · Waltham, United States · Founded 2017 · $165.0M raised
- Headquarters
- Waltham, Massachusetts
- Employees
- 201–500
- Founded
- 2017
- Business Model
- B2B
- Website
- dyne-tx.com
- Total Funding
- $165.0M
- Last Round
- $115.0M Series BAug 2020
- Rounds
- 2
- Type
- Public
About
Dyne Therapeutics is a clinical-stage biopharma developing targeted nucleic acid therapies for neuromuscular diseases. FORCE platform targets DMD, DM1, FSHD.
Summary
Dyne Therapeutics is a Biotech company based in Waltham, United States, founded in 2017. It has raised $165.0M in total across 2 rounds, most recently a $115.0M Series B round in Aug 2020. Investors include Atlas Venture, Hercules Capital and Forbion Capital Partners.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Jun 2025
Sign up to see all 4 rounds
Series A through Debt Financing — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/dyne-therapeutics"><img src="https://indexed.vc/api/badge/company/dyne-therapeutics" alt="Dyne Therapeutics on Indexed.vc" width="260" height="76" /></a>